Oncocyte’s DetermaIO Immuno-Oncology Assay Predicts Response to Atezolizumab in Phase 2 Clinical Trial

Results published in peer-reviewed journal, Clinical Cancer Research

Study validates DetermaIO’s utility in identifying breast cancer patients most likely to benefit from atezolizumab

Read more at globenewswire.com